Pinna A, Zaccheddu F, Boscia F, Carru C, Solinas G
IV (weekly): 250 mg/week or 500 mg/week , depending on the infusion length/volume
Reported targets & pathways GHRH receptor Ghrelin / GHS-R1a receptor Pituitary somatotroph GH release IGF-1 axis Selected research Published studies on CJC-1295 + Ipamorelin Blend Peer-reviewed references for further reading
K., Monnet, A., Wary, C., Duteil, S
For component-level research details and citations, researchers should reference the KLOW research hub when available, along with individual component resources for BPC-157, TB-500, GHK-Cu, and KPV
It also supports cell growth by influencing the production of growth factors like VEGF (vascular endothelial growth factor), essential for tissue regeneration